Tamoxifen curative effect prediction related SNP (Single Nucleotide Polymorphism) site detection primer group and kit based on nucleic acid mass spectrum platform
Through the SNP site detection primer set and kit based on the nucleic acid mass spectrometry platform, the problem of drug resistance detection in breast cancer patients is solved, and a fast and low-cost personalized treatment plan is achieved, which meets the The need for multi-gene loci detection improves the therapeutic effect.
Patent Information
- Application Number
- CN202411321094.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-20
- Publication Date
- 2024-12-03
AI Technical Summary
Existing breast cancer patients have drug resistance problems when receiving tamoxifen treatment, resulting in poor treatment results. The existing testing methods cannot meet the testing needs of multiple genes and multiple sites, and the high-throughput technology costs are high. , long cycles, and it is difficult to popularize in clinical practice.
It provides a primer set and kit for detecting SNP site related to tamoxifen efficacy prediction based on the nucleic acid mass spectrometry platform, which is used to quickly and at low cost to detect rs10509373, rs4646, rs3892097, rs1065852 and other sites to achieve personalized drug treatment.
It achieves accurate prediction of the efficacy of tamoxifen, shortens the detection cycle, reduces costs, supports individualized drug treatment, and is suitable for single-platform multi-gene loci detection.
Smart Images

Figure CN119061126A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of gene SNP site detection, and specifically to a primer set and a kit for detecting SNP sites related to tamoxifen efficacy prediction based on a nucleic acid mass spectrometry platform. Background Art
[0002] Breast cancer is the malignant tumor with the highest morbidity and mortality rate among Chinese women, and it seriously threatens the health of Chinese women. Among Chinese female breast cancer patients, 60%-70% are estrogen receptor-positive breast cancer patients. Clinically, these patients need endocrine therapy.
[0003] Tamoxifen (TAM) is a standard endocrine therapy drug for breast cancer patients. It is often used in the adjuvant treatment of recurrent and metastatic breast cancer in women and postoperative metastasis of breast cancer, as well as the prevention of recurrence. However, the anti-estrogen activity of TAM itself is very weak, and it must be metabolized into activated 4-hydroxy-tamoxifen (4-0H-TAM) in the human body, which has strong anti-estrogen activity. However, nearly 30%-50% of patients develop drug resistance during tamoxifen treatment, which poses an important challenge to subsequent treatment plans.
[0004] CYP2D6 is one of the important cytochrome P450 oxidative metabolic enzymes, accounting for 2%-9% of the total liver enzymes and participating in the metabolism of 20%-30% of drugs. The gene polymorphism is closely related to poor drug efficacy and toxic side effects. Drug metabolomics studies have found that TAM is mainly converted into active metabolites through the action of rate-limiting enzymes such as CYP2D6. Different rate-limiting enzyme phenotypes may have different effects on the efficacy and adverse reactions of TAM. Patients carrying the CYP2D6 poor metabolizer gene produce lower concentrations of Endoxifen, and the therapeutic effect of tamoxifen may be poor, resulting in different responsiveness of breast cancer patients with different genotypes to tamoxifen (TAM), which in turn affects the prognosis of patients. The US FDA recommends that ER-positive breast cancer patients undergo CYP2D6 genotype testing before receiving TAM treatment to ensure the efficacy of the drug. Studies have shown that the Chinese population is mostly moderate metabolizers (carrying alleles that reduce enzyme function), so the level of Endoxifen in the patient's body will be lower, and the efficacy of TAM will be reduced. Given that China has a higher proportion of premenopausal patients and a high proportion of patients carrying alleles that reduce enzyme function, it is very important to find alternative treatment modes for this population. In addition to CYP2D6, other studies have shown that C10orf11 rs10509373 and CYP19A1 rs4646 indicate adverse clinical outcomes in breast cancer TAMs and are associated with shorter recurrence-free survival.
[0005] The mechanism of tamoxifen resistance is complex and involves the interaction of multiple intracellular signaling pathways. It is of great significance to identify biomarkers that predict patients' response to tamoxifen by studying the mechanism of tamoxifen resistance and providing genetic testing for tamoxifen resistance in breast cancer. Currently, there are many detection methods with their own characteristics. PCR-based detection methods, such as ARMS-PCR, fluorescent quantitative PCR, etc., are easy to operate, fast, and simple to analyze data. However, due to the limitation of throughput, they cannot meet the clinical needs for multiple genes and multiple sites detection. High-throughput gene detection technology, such as high-throughput sequencing technology, solves the limitation of throughput, but it is costly, has a long detection cycle, and has high technical requirements for experimental operators and data analysts. Therefore, it has not yet been widely used in clinical testing.
[0006] Therefore, there is an urgent need for an economical, rapid, and easy-to-operate detection method to predict the dosage of tamoxifen for different individuals in a personalized manner to meet the needs of accurate medication and treatment. Summary of the invention
[0007] The present invention provides a primer set and a kit for detecting SNP sites related to tamoxifen efficacy prediction based on a nucleic acid mass spectrometry platform, which are used to detect and type SNP sites at low cost, quickly and conveniently, so as to predict the tamoxifen dosage for different individuals in a personalized manner, thereby meeting the needs of accurate medication and treatment.
[0008] In view of this, the scheme of the present invention is:
[0009] The first aspect of the present invention provides a primer set for detecting SNP sites related to tamoxifen efficacy prediction, which is a primer set for detecting rs10509373, rs4646, rs3892097, and rs1065852; specifically, it includes a PCR amplification primer set with nucleotide sequences as shown in SEQ ID NO: 1-8.
[0010] Furthermore, the primer set also includes a single base extension primer set with nucleotide sequences as shown in SEQ ID NOs: 9-12.
[0011] The second aspect of the present invention provides the use of the primer set described in the first aspect in preparing a product for SNP site typing detection or tamoxifen efficacy prediction.
[0012] The third aspect of the present invention is to provide a tamoxifen efficacy prediction-related SNP site detection kit based on a nucleic acid mass spectrometry platform, wherein the detection kit comprises a PCR amplification primer set having a nucleotide sequence as shown in SEQ ID NO: 1-8, and a single base extension primer set having a nucleotide sequence as shown in SEQ ID NO: 9-12.
[0013] Furthermore, the kit also includes one or more of a PCR reaction reagent, a SAP reaction reagent and a single base extension reaction reagent.
[0014] Preferably, the multiplex PCR reaction reagents include PCR reaction buffer, Mg 2+ , dNTPs, DNA polymerase, and one or more of water; SAP reaction is a shrimp alkaline phosphatase digestion reaction, and the reagents include SAP reaction buffer, SAP enzyme, and one or more of water; single base extension reaction reagents include single base extension reaction buffer, single base extension reaction termination solution, single base extension reaction enzyme, and one or more of water.
[0015] The fourth aspect of the present invention proposes a tamoxifen efficacy prediction-related SNP site detection reaction system based on a nucleic acid mass spectrometry platform, the reaction system comprising a PCR amplification reaction system and a single base extension reaction system; the PCR amplification reaction system contains a PCR amplification primer set, the nucleotide sequence of the PCR amplification primer set is shown in SEQ ID NO: 1-8; the single base extension reaction system contains a single base extension primer set, the nucleotide sequence of the single base extension primer set is shown in SEQ ID NO: 9-12.
[0016] Furthermore, the reaction system also includes one or more of a PCR reaction reagent, a SAP reaction reagent and a single base extension reaction reagent.
[0017] Preferably, the multiplex PCR reaction reagents include PCR reaction buffer, Mg 2+ , dNTPs, DNA polymerase, and one or more of water; SAP reaction is a shrimp alkaline phosphatase digestion reaction, and the reagents include SAP reaction buffer, SAP enzyme, and one or more of water; single base extension reaction reagents include single base extension reaction buffer, single base extension reaction termination solution, single base extension reaction enzyme, and one or more of water.
[0018] Furthermore, in the PCR amplification reaction system, the concentration of each PCR amplification primer having a nucleotide sequence as shown in SEQ ID NO: 1-8 is 0.5 μM.
[0019] Furthermore, in the single base extension reaction system, the concentrations of the single base extension primers having nucleotide sequences as shown in SEQ ID NOs: 9-12 are 5.4 μM, 5.8 μM, 6.6 μM, and 7.6 μM.
[0020] The fifth aspect of the present invention provides a tamoxifen efficacy prediction-related SNP site detection system based on a nucleic acid mass spectrometry platform, which is characterized by comprising the reaction system described in the fourth aspect, a desalting resin, and a spotting chip.
[0021] Compared with the prior art, the present invention has the following beneficial effects:
[0022] The present invention is designed for the main mutation sites related to the prediction of tamoxifen efficacy, and can realize specific detection of site mutations related to the prediction of tamoxifen efficacy with high accuracy. The detection results cover a total of four mutation sites, namely rs10509373, rs4646, rs3892097, and rs1065852, which can greatly shorten the detection cycle and reduce the detection cost. In addition, it can be applied to a single platform to realize the detection of multiple gene sites, providing a reference for individualized tamoxifen drug treatment.
[0023] The primer set provided by the present invention is obtained by modification optimization and large sample test screening. All primer sequences can accurately type the samples and can also meet the requirements of mass spectrometry detection technology, thereby realizing the rapid and effective detection of tamoxifen efficacy prediction using a nucleic acid mass spectrometry platform. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 This is a MassArray result diagram of the rs10509373 site provided in Example 1 of the present invention.
[0025] Figure 2 This is a MassArray result diagram of the rs4646 locus provided in Example 1 of the present invention.
[0026] Figure 3 This is a MassArray result diagram of the rs3892097 site provided in Example 1 of the present invention.
[0027] Figure 4 This is a MassArray result diagram of the rs1065852 site provided in Example 1 of the present invention. DETAILED DESCRIPTION
[0028] The technical solution of the present invention will be clearly and completely described below in conjunction with the preferred embodiments. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0029] In one embodiment, the primer set provided for detecting SNP sites related to tamoxifen efficacy prediction is designed for the main mutation sites related to tamoxifen efficacy prediction, and can realize specific detection of site mutations related to tamoxifen efficacy prediction, with high accuracy, and the test results cover 4 mutation sites in 4 genes including C10orf11, CYP19A1, CYP2D6, and CYP2D6*10, which can greatly shorten the detection cycle and reduce the detection cost; and, realize the detection of multiple gene sites on a single platform, and provide a reference for individualized tamoxifen drug therapy. In addition, the primer set provided by the present invention is obtained by changing optimization and large sample test screening, and all primer sequences can accurately type samples, and can also meet the requirements of mass spectrometry detection technology, so as to realize the application of MassARRAY platform for rapid and effective detection of tamoxifen efficacy prediction.
[0030] In an embodiment of the present invention, the SNP sites corresponding to the prediction of tamoxifen efficacy include: rs10509373, rs4646, rs3892097, and rs1065852.
[0031] It can be understood that the primer pair is a PCR primer pair. In a specific embodiment, when the actual application requires an extension primer, the primer set also includes 4 extension primers. When designing the above 4 target SNP sites, professional software is used to confirm other SNP sites upstream and downstream of each site that account for more than 1% of the total, and avoid coverage when designing amplification primers and extension primers to reduce their impact on detection.
[0032] It can be understood that the primer pairs and extension primers correspond one to one, and the corresponding primer pairs and extension primers are used to detect the nucleotide at the same site.
[0033] Further, the genotypes of each site are listed as follows:
[0034]
[0035] In an embodiment of the present invention, the tamoxifen efficacy prediction test detects C10ORF11, CYP19A1, CYP2D6, and CYP2D6*10 4 genes in the human body by means of gene detection technology to find out the predicted levels of tamoxifen efficacy in different individuals.
[0036] It should be noted that in order to save samples and costs as much as possible in the pre-test of tamoxifen efficacy, all four SNP sites are tested in the same test well.
[0037] It is understandable that there will be multiple pairs of PCR amplification primers in the detection well. To ensure the accuracy and specificity of the test, primers are designed for multiple PCR when designing amplification primers, and the design results are compared with the human genome using a professional website (https: / / www.ncbi.nlm.nih.gov / ) to confirm that there is no non-specific match. In order to avoid interference of amplification primers on the test results, specific prefixes are added during primer design to increase primer quality and eliminate interference.
[0038] It is understandable that there will be multiple extension primers in the detection well. In order to ensure that the detection results of each site do not interfere with each other, professional software is used to design the extension primers to different masses. At the same time, the mass of each primer before and after extension is calculated through manual verification, and unqualified primers are designed separately.
[0039] Specifically, the correspondence between the detection sites and the types of diseases is as follows:
[0040]
[0041] The main reagent information used in the following examples is shown in Table 1.
[0042] Table 1: Main reagents
[0043]
[0044] The main instrument information used in the following examples is shown in Table 2.
[0045] Table 2: Main instruments
[0046]
[0047] Example 1 Primer design and reaction system establishment
[0048] Through MassARRAY primer design software (Assay Design Suite), adjust the relevant parameters, pre-design the primers for PCR and UEP of 8 sites, export the designed primers and parameter files, and synthesize the primers. For fragments of different molecular weights, the detection efficiency of the nucleic acid mass spectrometer is different. In order to make the detection efficiency of each site reach a more consistent level, it is necessary to adjust the extension primer UEP in the system to an appropriate concentration. The specific method is as follows:
[0049] Dilute 1μL UEP mix to 25μL with ultrapure water, perform nucleic acid mass spectrometry detection according to the general process, and compare the peak height of each UEP primer. According to the amount of each UEP primer added and the peak height, add the UEP primer of the corresponding site in direct proportion, and finally make the lowest peak height of each site UEP half of the highest peak height. Figure 1 , Figure 2 The specific peak graphs before and after the adjustment of UEP primers are listed respectively. (Table 3 and Table 4 are the preparation tables of PCR primer mix and UEP primer mix after adjustment respectively), and then the primers are tested and optimized.
[0050] Table 3: PCR primer mix preparation
[0051] Well SNP_ID add(μl) W1 rs10509373 1 / 1 W1 rs4646 1 / 1 W1 rs3892097 1 / 1 W1 rs1065852 1 / 1 W1 water 196
[0052] Table 4: UEP primer mix preparation
[0053] Well SNP_ID add(μl) W1 rs10509373 2.2 W1 rs4646 2.3 W1 rs3892097 2.6 W1 rs1065852 3.0 W1 water 189.8
[0054] The specific steps are as follows:
[0055] (1) Dilute the genomic DNA sample to 10 ng / μL and prepare the PCR reaction MIX according to Table 5 (the following is the amount of a single sample)
[0056] Table 5: PCR reaction system
[0057]
[0058] Seal the film, vortex mix for 30 seconds, centrifuge at 4000 rpm for 1 minute, and place the plate on the PCR instrument for the following thermal cycles:
[0059]
[0060] (2) Shrimp alkaline phosphatase digestion (SAP)
[0061] Take out the PCR plate, centrifuge at 4000 rpm for 1 minute, and prepare the SAP reaction system according to Table 6 (the following is the amount of a single sample):
[0062] Table 6: SAP reaction system
[0063]
[0064]
[0065] Add 2 μL of SAP mixture to each reaction well, seal the film, vortex mix for 30 seconds, centrifuge at 4000 rpm for 1 minute, and place the plate on the PCR instrument for the following thermal cycle:
[0066] Temperature(℃) time 37 40min 85 5min 10 Insulation
[0067] (3) Single base extension (EXT)
[0068] Take out the PCR plate, centrifuge at 4000 rpm for 1 minute, and prepare the EXT reaction system according to the following table, where Extend PrimerMix is a mixture of four sets of extension primers with different sites (the following is the amount of a single sample):
[0069] Table 7: EXT reaction system
[0070]
[0071] Add 2 μL of extension mixture to each reaction well, seal the membrane, vortex mix for 30 seconds, centrifuge at 4000 rpm for 1 minute, and place the plate on a PCR instrument for the following thermal cycles:
[0072]
[0073] (4) Resin desalting and dispensing
[0074] The samples were desalted by resin using MassARRAY CPM and spotted onto the corresponding SpectroCHIP (chip).
[0075] (5) MALDI-TOF
[0076] The data were obtained using a MALDI-TOF (matrix-assisted laser desorption ionization-time of flight) mass spectrometer. Taking the EDT12267925B1D1 sample test as an example, the MassARRAY test results of each point are shown in Figure 1-4 .
[0077] For specific primer sequences, see the primer sequences in Tables 8 and 9.
[0078] Table 8: PCR primer sequences
[0079]
[0080] Table 9: UEP primer sequences
[0081]
[0082] Example 2 Verification of the reaction system
[0083] In the process of system optimization in this embodiment, each detection site has 50 samples with known results (4 Sanger and 46 MassArray) for verification. The comparison results are consistent, confirming that the detection results are accurate. After confirming the optimal reaction system, the accuracy verification experiment was carried out. The specific verification scheme is as follows:
[0084] (1) Accuracy test verification plan: 50 samples were used to complete the accuracy test (see Table 10), and the test results were compared with the original results. If the consistency was greater than 95%, the verification was passed.
[0085] The specific verification process is as follows: first, the amplification primer MIX and the extension primer MIX are prepared according to the system addition table provided in Example 1, and then the steps of PCR amplification, shrimp alkaline phosphatase consumption, single base extension, resin desalting and MassARRAY CPM spot analysis are performed according to the operating steps in Example 1, and the results are analyzed. The accuracy and precision results are shown in Tables 10 and 11 below.
[0086] Table 10: Raw validation results for accuracy
[0087]
[0088]
[0089] Table 11: MassARRAY validation results for accuracy
[0090]
[0091]
[0092] Comparison of the MassARRAY results of 50 samples with the original results shows that the accuracy of the system verification experiment of the present invention is 100%.
[0093] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. A primer set for detecting SNP sites related to the prediction of tamoxifen efficacy, characterized in that: The present invention comprises a PCR amplification primer set having nucleotide sequences as shown in SEQ ID NO: 1-8.
2. The primer set according to claim 1, characterized in that Also included are single base extension primer sets whose nucleotide sequences are shown as SEQ ID NOs: 9-12.
3. Use of the primer set according to claim 1 or 2 in preparing a product for SNP site typing detection or tamoxifen efficacy prediction.
4. A tamoxifen efficacy prediction-related SNP site detection kit based on a nucleic acid mass spectrometry platform, characterized in that: It includes a PCR amplification primer set with nucleotide sequences as shown in SEQ ID NOs: 1-8, and a single base extension primer set with nucleotide sequences as shown in SEQ ID NOs: 9-12.
5. The kit according to claim 4, characterized in that The kit further comprises one or more of a PCR reaction reagent, a SAP reaction reagent and a single base extension reaction reagent.
6. A tamoxifen efficacy prediction-related SNP site detection reaction system based on a nucleic acid mass spectrometry platform, characterized in that: It comprises a PCR amplification reaction system and a single base extension reaction system; the PCR amplification reaction system comprises a PCR amplification primer set, and the nucleotide sequence of the PCR amplification primer set is shown in SEQ ID NO: 1-8; the single base extension reaction system comprises a single base extension primer set, and the nucleotide sequence of the single base extension primer set is shown in SEQ ID NO: 9-12.
7. The reaction system according to claim 6, characterized in that The reaction system also includes one or more of a PCR reaction reagent, a SAP reaction reagent and a single base extension reaction reagent.
8. The reaction system according to claim 6, characterized in that: In the PCR amplification reaction system, the concentration of each PCR amplification primer with a nucleotide sequence as shown in SEQ ID NO: 1-8 is 0.5 μM.
9. The reaction system according to claim 6, characterized in that: In the single base extension reaction system, the concentrations of the single base extension primers with nucleotide sequences as shown in SEQ ID NOs: 9-12 are 5.4 μM, 5.8 μM, 6.6 μM, and 7.6 μM, respectively.
10. A tamoxifen efficacy prediction-related SNP site detection system based on a nucleic acid mass spectrometry platform, characterized in that: The method comprises the reaction system according to any one of claims 6 to 9, a desalting resin and a spotting chip.
